Proton and Heavy Particle Intracranial Radiosurgery
Authors:
- Eric J. LehrerELEric J. Lehrer
- Arpan V. PrabhuArpan V. Prabhu
- Kunal K. SindhuKSKunal K. Sindhu
- Stanislav LazarevSLStanislav Lazarev
- Henry Ruiz-GarciaHRHenry Ruiz-Garcia
- Jennifer L. PetersonJPJennifer L. Peterson
- Chris BeltranChris Beltran
- Keith FurutaniKeith Furutani
- David SchlesingerDSDavid Schlesinger
- Jason P. SheehanJSJason P. Sheehan
- Daniel M. TrifilettiDTDaniel M. Trifiletti
Open Access
- 3 January 2021
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 9 (1) , 31
Abstract
Stereotactic radiosurgery (SRS) involves the delivery of a highly conformal ablative dose of radiation to both benign and malignant targets. This has traditionally been accomplished in a single fraction; however, fractionated approaches involving five or fewer treatments have been delivered for larger lesions, as well as lesions in close proximity to radiosensitive structures. The clinical utilization of SRS has overwhelmingly involved photon-based sources via dedicated radiosurgery platforms (e.g., Gamma Knife® and Cyberknife®) or specialized linear accelerators. While photon-based methods have been shown to be highly effective, advancements are sought for improved dose precision, treatment duration, and radiobiologic effect, among others, particularly in the setting of repeat irradiation. Particle-based techniques (e.g., protons and carbon ions) may improve many of these shortcomings. Specifically, the presence of a Bragg Peak with particle therapy at target depth allows for marked minimization of distal dose delivery, thus mitigating the risk of toxicity to organs at risk. Carbon ions also exhibit a higher linear energy transfer than photons and protons, allowing for greater relative biological effectiveness. While the data are limited, utilization of proton radiosurgery in the setting of brain metastases has been shown to demonstrate 1-year local control rates >90%, which are comparable to that of photon-based radiosurgery. Prospective studies are needed to further validate the safety and efficacy of this treatment modality. We aim to provide a comprehensive overview of clinical evidence in the use of particle therapy-based radiosurgery.Keywords
This publication has 115 references indexed in Scilit:
- Range uncertainties in proton therapy and the role of Monte Carlo simulationsPhysics in Medicine & Biology, 2012
- The convergence of radiation and immunogenic cell death signaling pathwaysFrontiers in Oncology, 2012
- Heavy charged particle radiobiology: Using enhanced biological effectiveness and improved beam focusing to advance cancer therapyMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2011
- Annual Report to the Nation on the Status of Cancer, 1975-2007, Featuring Tumors of the Brain and Other Nervous SystemJNCI: Journal of the National Cancer Institute, 2011
- Epidemiology and etiology of meningiomaJournal of Neuro-Oncology, 2010
- Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trialThe Lancet Oncology, 2009
- Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance SystemJournal of Clinical Oncology, 2004
- Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trialThe Lancet, 2004
- Postoperative Radiotherapy in the Treatment of Single Metastases to the BrainJAMA, 1998
- A Randomized Trial of Surgery in the Treatment of Single Metastases to the BrainNew England Journal of Medicine, 1990